NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Aligos Therapeutics, Inc. ALGS
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.2M
▼ 39.5% vs FY2024
EPS · FY25
$-2.45
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-196.9%
Net margin · FY25
-1106.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.2M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 1107 cents on every revenue dollar this year.
Per share
USD -2.45
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-196.9%
Return on equity, FY2025
ROE
Operating margin-4024.9%
Net margin-1106.7%
Return on assets-30.5%
Each USD of equity lost 197 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 88.5M
total assets, end of FY2025
Total assetsUSD 88.5M
EquityUSD 53.5M
CashUSD 18.3M
Current ratio3.90×
Equity funds 60% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−2.45
−20.94
−34.20
−2.25
−3.22
−10.87
−26.04
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−196.9
−415.8
−89.5
−66.6
−63.4
−139.9
·
Shares out B
0.01
0.00
0.00
0.04
0.04
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed